Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: Results from a randomised European-Australian phase 3 trial

1. Khullar, V.
2. Amarenco, G.
3. Angulo, J.C.
4. Cambronero, J.
5. Høye, K.
6. Milsom, I.
7. Radziszewski, P.
8. Rechberger, T.
9. Boerrigter, P.
10. Drogendijk, T.
11. Wooning, M.
12. Chapple, C.